These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33080969)

  • 1. Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer.
    Park JY; Chae JR; Cho YL; Kim Y; Lee D; Lee JK; Kang WJ
    Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33080969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging.
    Dong L; Zhou H; Zhao M; Gao X; Liu Y; Liu D; Guo W; Hu H; Xie Q; Fan J; Lin J; Wu W
    Mol Ther Nucleic Acids; 2018 Dec; 13():376-386. PubMed ID: 30347351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma.
    Wu T; Song Z; Huang H; Jakos T; Jiang H; Xie Y; Zhu J
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109393. PubMed ID: 36375323
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhao M; Dong L; Liu Z; Yang S; Wu W; Lin J
    Quant Imaging Med Surg; 2018 Mar; 8(2):151-160. PubMed ID: 29675356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure based innovative approach to analyze aptaprobe-GPC3 complexes in hepatocellular carcinoma.
    Shin WR; Park DY; Kim JH; Lee JP; Thai NQ; Oh IH; Sekhon SS; Choi W; Kim SY; Cho BK; Kim SC; Min J; Ahn JY; Kim YH
    J Nanobiotechnology; 2022 Apr; 20(1):204. PubMed ID: 35477501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of CD44E/s dual-targeting DNA aptamer as nanoprobe to deliver treatment in hepatocellular carcinoma.
    Lo CW; Chan CKW; Yu J; He M; Choi CHJ; Lau JYW; Wong N
    Nanotheranostics; 2022; 6(2):161-174. PubMed ID: 34976591
    [No Abstract]   [Full Text] [Related]  

  • 7. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
    Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
    Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3-Targeted
    Labadie KP; Hamlin DK; Kenoyer A; Daniel SK; Utria AF; Ludwig AD; Kenerson HL; Li L; Sham JG; Chen DL; Orozco JJ; Yeung RS; Orvig C; Li Y; Wilbur DS; Park JO
    J Nucl Med; 2022 Jul; 63(7):1033-1038. PubMed ID: 34772791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma.
    Fang Y; Ma H; Zhang X; Zhang P; Li Y; He S; Sheng C; Dong G
    Eur J Med Chem; 2024 Jan; 264():116047. PubMed ID: 38118394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
    Bi Y; Jiang H; Wang P; Song B; Wang H; Kong X; Li Z
    Oncotarget; 2017 Aug; 8(32):52866-52876. PubMed ID: 28881778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer.
    Park JY; Cho YL; Chae JR; Moon SH; Cho WG; Choi YJ; Lee SJ; Kang WJ
    Mol Ther Nucleic Acids; 2018 Sep; 12():543-553. PubMed ID: 30195790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.
    Nishida T; Kataoka H
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31510063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.